YS001 / JiangSu WuZhong Pharma, Hangzhou Yusheng - LARVOL DELTA

Wuzhong Pharma’s PI3K/mTOR dual targeted drug set for trial in China (GBI Health) - "China-based Jiangsu Wuzhong Pharmaceutical Group Corp., ( 600200.SHE) announced that its subsidiary Suzhou Zerun New Drug Development Co., Ltd’s (GBI translation) Category 1 drug YS001 was awarded approval to enter clinical trials by the National Medical Products Administration. The targeted indication is advanced malignant solid tumors."

New trial • Oncology • Solid Tumor

Wuzhong Pharma’s PI3K/mTOR inhibitor under trial review in China (GBI Health) - "China-based Jiangsu Wuzhong Pharmaceutical Group Corp., announced that the clinical trial filing for its YS001, a Category 1 cancer drug developed by subsidiary Suzhou Zerun Pharmaceutical Research and Development Co., Ltd (GBI translation), has been accepted for review by the National Medical Products Administration. YS001, an in-house developed PI3K/mTOR dual-targeted inhibitor with intellectual property rights in China, is under development to treat advanced malignant solid tumors such as breast cancer, kidney cancer, stomach cancer, and ovarian cancer."

Non-US regulatory • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor